Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study
The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tsutsui, Hiroyuki [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The energy challenge: energy and Environment Knowledge Week E2KW 2013 - Sáez-Martínez, Francisco J. ELSEVIER, 2015transfer abstract, official journal of the Japanese College of Cardiology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:70 ; year:2017 ; number:3 ; pages:225-231 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jjcc.2016.11.011 |
|---|
| Katalog-ID: |
ELV035961031 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035961031 | ||
| 003 | DE-627 | ||
| 005 | 20230625210151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jjcc.2016.11.011 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017013000026.pica |
| 035 | |a (DE-627)ELV035961031 | ||
| 035 | |a (ELSEVIER)S0914-5087(16)30309-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 690 |q VZ |
| 082 | 0 | 4 | |a 330 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.18 |2 bkl | ||
| 100 | 1 | |a Tsutsui, Hiroyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. | ||
| 520 | |a The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. | ||
| 650 | 7 | |a Sacubitril/valsartan |2 Elsevier | |
| 650 | 7 | |a LCZ696 |2 Elsevier | |
| 650 | 7 | |a Heart failure with reduced ejection fraction |2 Elsevier | |
| 650 | 7 | |a Neprilysin |2 Elsevier | |
| 650 | 7 | |a Japanese |2 Elsevier | |
| 700 | 1 | |a Momomura, Shinichi |4 oth | |
| 700 | 1 | |a Saito, Yoshihiko |4 oth | |
| 700 | 1 | |a Ito, Hiroshi |4 oth | |
| 700 | 1 | |a Yamamoto, Kazuhiro |4 oth | |
| 700 | 1 | |a Ohishi, Tomomi |4 oth | |
| 700 | 1 | |a Okino, Naoko |4 oth | |
| 700 | 1 | |a Guo, Weinong |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Sáez-Martínez, Francisco J. ELSEVIER |t The energy challenge: energy and Environment Knowledge Week E2KW 2013 |d 2015transfer abstract |d official journal of the Japanese College of Cardiology |g Amsterdam [u.a.] |w (DE-627)ELV018703259 |
| 773 | 1 | 8 | |g volume:70 |g year:2017 |g number:3 |g pages:225-231 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jjcc.2016.11.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 35.18 |j Kolloidchemie |j Grenzflächenchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 70 |j 2017 |e 3 |h 225-231 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
h t ht |
|---|---|
| matchkey_str |
tsutsuihiroyukimomomurashinichisaitoyosh:2017----:fiaynsftoscbtivlatnc66naaeeainsihhoihatalradeueeetofatortoaeoade |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
35.18 |
| publishDate |
2017 |
| allfields |
10.1016/j.jjcc.2016.11.011 doi GBVA2017013000026.pica (DE-627)ELV035961031 (ELSEVIER)S0914-5087(16)30309-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl Tsutsui, Hiroyuki verfasserin aut Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Elsevier Momomura, Shinichi oth Saito, Yoshihiko oth Ito, Hiroshi oth Yamamoto, Kazuhiro oth Ohishi, Tomomi oth Okino, Naoko oth Guo, Weinong oth Enthalten in Elsevier Sáez-Martínez, Francisco J. ELSEVIER The energy challenge: energy and Environment Knowledge Week E2KW 2013 2015transfer abstract official journal of the Japanese College of Cardiology Amsterdam [u.a.] (DE-627)ELV018703259 volume:70 year:2017 number:3 pages:225-231 extent:7 https://doi.org/10.1016/j.jjcc.2016.11.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 35.18 Kolloidchemie Grenzflächenchemie VZ AR 70 2017 3 225-231 7 045F 610 |
| spelling |
10.1016/j.jjcc.2016.11.011 doi GBVA2017013000026.pica (DE-627)ELV035961031 (ELSEVIER)S0914-5087(16)30309-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl Tsutsui, Hiroyuki verfasserin aut Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Elsevier Momomura, Shinichi oth Saito, Yoshihiko oth Ito, Hiroshi oth Yamamoto, Kazuhiro oth Ohishi, Tomomi oth Okino, Naoko oth Guo, Weinong oth Enthalten in Elsevier Sáez-Martínez, Francisco J. ELSEVIER The energy challenge: energy and Environment Knowledge Week E2KW 2013 2015transfer abstract official journal of the Japanese College of Cardiology Amsterdam [u.a.] (DE-627)ELV018703259 volume:70 year:2017 number:3 pages:225-231 extent:7 https://doi.org/10.1016/j.jjcc.2016.11.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 35.18 Kolloidchemie Grenzflächenchemie VZ AR 70 2017 3 225-231 7 045F 610 |
| allfields_unstemmed |
10.1016/j.jjcc.2016.11.011 doi GBVA2017013000026.pica (DE-627)ELV035961031 (ELSEVIER)S0914-5087(16)30309-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl Tsutsui, Hiroyuki verfasserin aut Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Elsevier Momomura, Shinichi oth Saito, Yoshihiko oth Ito, Hiroshi oth Yamamoto, Kazuhiro oth Ohishi, Tomomi oth Okino, Naoko oth Guo, Weinong oth Enthalten in Elsevier Sáez-Martínez, Francisco J. ELSEVIER The energy challenge: energy and Environment Knowledge Week E2KW 2013 2015transfer abstract official journal of the Japanese College of Cardiology Amsterdam [u.a.] (DE-627)ELV018703259 volume:70 year:2017 number:3 pages:225-231 extent:7 https://doi.org/10.1016/j.jjcc.2016.11.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 35.18 Kolloidchemie Grenzflächenchemie VZ AR 70 2017 3 225-231 7 045F 610 |
| allfieldsGer |
10.1016/j.jjcc.2016.11.011 doi GBVA2017013000026.pica (DE-627)ELV035961031 (ELSEVIER)S0914-5087(16)30309-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl Tsutsui, Hiroyuki verfasserin aut Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Elsevier Momomura, Shinichi oth Saito, Yoshihiko oth Ito, Hiroshi oth Yamamoto, Kazuhiro oth Ohishi, Tomomi oth Okino, Naoko oth Guo, Weinong oth Enthalten in Elsevier Sáez-Martínez, Francisco J. ELSEVIER The energy challenge: energy and Environment Knowledge Week E2KW 2013 2015transfer abstract official journal of the Japanese College of Cardiology Amsterdam [u.a.] (DE-627)ELV018703259 volume:70 year:2017 number:3 pages:225-231 extent:7 https://doi.org/10.1016/j.jjcc.2016.11.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 35.18 Kolloidchemie Grenzflächenchemie VZ AR 70 2017 3 225-231 7 045F 610 |
| allfieldsSound |
10.1016/j.jjcc.2016.11.011 doi GBVA2017013000026.pica (DE-627)ELV035961031 (ELSEVIER)S0914-5087(16)30309-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl Tsutsui, Hiroyuki verfasserin aut Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Elsevier Momomura, Shinichi oth Saito, Yoshihiko oth Ito, Hiroshi oth Yamamoto, Kazuhiro oth Ohishi, Tomomi oth Okino, Naoko oth Guo, Weinong oth Enthalten in Elsevier Sáez-Martínez, Francisco J. ELSEVIER The energy challenge: energy and Environment Knowledge Week E2KW 2013 2015transfer abstract official journal of the Japanese College of Cardiology Amsterdam [u.a.] (DE-627)ELV018703259 volume:70 year:2017 number:3 pages:225-231 extent:7 https://doi.org/10.1016/j.jjcc.2016.11.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 35.18 Kolloidchemie Grenzflächenchemie VZ AR 70 2017 3 225-231 7 045F 610 |
| language |
English |
| source |
Enthalten in The energy challenge: energy and Environment Knowledge Week E2KW 2013 Amsterdam [u.a.] volume:70 year:2017 number:3 pages:225-231 extent:7 |
| sourceStr |
Enthalten in The energy challenge: energy and Environment Knowledge Week E2KW 2013 Amsterdam [u.a.] volume:70 year:2017 number:3 pages:225-231 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Kolloidchemie Grenzflächenchemie |
| institution |
findex.gbv.de |
| topic_facet |
Sacubitril/valsartan LCZ696 Heart failure with reduced ejection fraction Neprilysin Japanese |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The energy challenge: energy and Environment Knowledge Week E2KW 2013 |
| authorswithroles_txt_mv |
Tsutsui, Hiroyuki @@aut@@ Momomura, Shinichi @@oth@@ Saito, Yoshihiko @@oth@@ Ito, Hiroshi @@oth@@ Yamamoto, Kazuhiro @@oth@@ Ohishi, Tomomi @@oth@@ Okino, Naoko @@oth@@ Guo, Weinong @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV018703259 |
| dewey-sort |
3610 |
| id |
ELV035961031 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035961031</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625210151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jjcc.2016.11.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017013000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035961031</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0914-5087(16)30309-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.18</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tsutsui, Hiroyuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sacubitril/valsartan</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LCZ696</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Heart failure with reduced ejection fraction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neprilysin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Japanese</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Momomura, Shinichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saito, Yoshihiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ito, Hiroshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Kazuhiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohishi, Tomomi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okino, Naoko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guo, Weinong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Sáez-Martínez, Francisco J. ELSEVIER</subfield><subfield code="t">The energy challenge: energy and Environment Knowledge Week E2KW 2013</subfield><subfield code="d">2015transfer abstract</subfield><subfield code="d">official journal of the Japanese College of Cardiology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV018703259</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:70</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:225-231</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jjcc.2016.11.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.18</subfield><subfield code="j">Kolloidchemie</subfield><subfield code="j">Grenzflächenchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">70</subfield><subfield code="j">2017</subfield><subfield code="e">3</subfield><subfield code="h">225-231</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Tsutsui, Hiroyuki |
| spellingShingle |
Tsutsui, Hiroyuki ddc 610 ddc 690 ddc 330 ddc 540 bkl 35.18 Elsevier Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study |
| authorStr |
Tsutsui, Hiroyuki |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV018703259 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 690 - Buildings 330 - Economics 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese Elsevier |
| topic |
ddc 610 ddc 690 ddc 330 ddc 540 bkl 35.18 Elsevier Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese |
| topic_unstemmed |
ddc 610 ddc 690 ddc 330 ddc 540 bkl 35.18 Elsevier Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese |
| topic_browse |
ddc 610 ddc 690 ddc 330 ddc 540 bkl 35.18 Elsevier Sacubitril/valsartan Elsevier LCZ696 Elsevier Heart failure with reduced ejection fraction Elsevier Neprilysin Elsevier Japanese |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s m sm y s ys h i hi k y ky t o to n o no w g wg |
| hierarchy_parent_title |
The energy challenge: energy and Environment Knowledge Week E2KW 2013 |
| hierarchy_parent_id |
ELV018703259 |
| dewey-tens |
610 - Medicine & health 690 - Building & construction 330 - Economics 540 - Chemistry |
| hierarchy_top_title |
The energy challenge: energy and Environment Knowledge Week E2KW 2013 |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV018703259 |
| title |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study |
| ctrlnum |
(DE-627)ELV035961031 (ELSEVIER)S0914-5087(16)30309-4 |
| title_full |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study |
| author_sort |
Tsutsui, Hiroyuki |
| journal |
The energy challenge: energy and Environment Knowledge Week E2KW 2013 |
| journalStr |
The energy challenge: energy and Environment Knowledge Week E2KW 2013 |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
225 |
| author_browse |
Tsutsui, Hiroyuki |
| container_volume |
70 |
| physical |
7 |
| class |
610 610 DE-600 690 VZ 330 VZ 540 VZ 35.18 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tsutsui, Hiroyuki |
| doi_str_mv |
10.1016/j.jjcc.2016.11.011 |
| dewey-full |
610 690 330 540 |
| title_sort |
efficacy and safety of sacubitril/valsartan (lcz696) in japanese patients with chronic heart failure and reduced ejection fraction: rationale for and design of the randomized, double-blind parallel-hf study |
| title_auth |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study |
| abstract |
The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. |
| abstractGer |
The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. |
| abstract_unstemmed |
The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 |
| container_issue |
3 |
| title_short |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study |
| url |
https://doi.org/10.1016/j.jjcc.2016.11.011 |
| remote_bool |
true |
| author2 |
Momomura, Shinichi Saito, Yoshihiko Ito, Hiroshi Yamamoto, Kazuhiro Ohishi, Tomomi Okino, Naoko Guo, Weinong |
| author2Str |
Momomura, Shinichi Saito, Yoshihiko Ito, Hiroshi Yamamoto, Kazuhiro Ohishi, Tomomi Okino, Naoko Guo, Weinong |
| ppnlink |
ELV018703259 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jjcc.2016.11.011 |
| up_date |
2024-07-06T18:55:52.485Z |
| _version_ |
1803857064084111360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035961031</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625210151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jjcc.2016.11.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017013000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035961031</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0914-5087(16)30309-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.18</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tsutsui, Hiroyuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sacubitril/valsartan</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LCZ696</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Heart failure with reduced ejection fraction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neprilysin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Japanese</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Momomura, Shinichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saito, Yoshihiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ito, Hiroshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Kazuhiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohishi, Tomomi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okino, Naoko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guo, Weinong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Sáez-Martínez, Francisco J. ELSEVIER</subfield><subfield code="t">The energy challenge: energy and Environment Knowledge Week E2KW 2013</subfield><subfield code="d">2015transfer abstract</subfield><subfield code="d">official journal of the Japanese College of Cardiology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV018703259</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:70</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:225-231</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jjcc.2016.11.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.18</subfield><subfield code="j">Kolloidchemie</subfield><subfield code="j">Grenzflächenchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">70</subfield><subfield code="j">2017</subfield><subfield code="e">3</subfield><subfield code="h">225-231</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400923 |